Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATR-002

            Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2021

            Details:

            RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Wacker Chemie AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 23, 2020

            Details:

            Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA-based vaccines

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Commission

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 16, 2020

            Details:

            The mRNA vaccine will be supplied once it has proven to be safe and effective against COVID-19. CureVac will receive an upfront payment to support the advanced clinical development of CVnCoV, to ramp-up its manufacturing network, and market launch and supply preparations.